This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This was a prospective cohort study. The patients on haloperidol or fluphenazine were discharged from a single hospital, while the patients on risperidone were from all hospitals in the area. The duration of the follow-up ranged from 12 to 21 months. No loss to follow-up was reported.
Analysis of effectiveness
The primary health outcome used in the analysis was the rate of rehospitalisation. There was no adjustment for possible confounders. The analysis was conducted using the reported hospitalisations for the participants studied.
Effectiveness results
For schizophrenic patients discharged with prescriptions for haloperidol decanoate and fluphenazine decanoate, the times courses to readmission differed but not significantly (chi-squared 0.21, d.f.=1, p=0.643).
The rehospitalisation rate for haloperidol recipients was 36% (95% confidence interval, CI: 11 -60) at 1 year and 44% (95% CI: 18 -70) at 2 years. The rehospitalisation rate for fluphenazine recipients was 21% (95% CI: 7 -35) at 1 year and 38% (95% CI: 20 -56) at 3 years.
The mean (+/-standard deviation) time spent in the community was 294 (+/-232) days for patients taking haloperidol, and 346 (+/-188) days for those taking fluphenazine.
The rehospitalisation rate for risperidone recipients was 17% (95% CI: 9 -25) at 1 year and 34% (95% CI: 20 -48) at 2 years.
The mean time spent in the community was 360 days for patients taking risperidone.
Clinical conclusions
Risperidone was more effective (although not statistically significantly so) than the depot antipsychotic agents.
Modelling
The rate of readmission for haloperidol decanoate or fluphenazine decanoate groups was estimated by Kaplan-Meier analysis.
Measure of benefits used in the economic analysis
The authors did not derive a measure of health benefit. The economic analysis should be considered as a costconsequences design since the benefits were associated with the effectiveness results.
Direct costs
The costs were not discounted because the length of follow-up in the study was less than 21 months. The direct costs included the hospitalisation rates and the drug treatment. The mean dose (+/-standard deviation) was 163.69 (+/-98.04) mg/month for haloperidol recipients, 86.21 (+/-65.11) mg/month for fluphenazine recipients, and 5.6 (+/-3.2) mg/day for risperidone recipients. The rates of hospitalisation were derived from the studies analysed. The same mean cost of
